Table 3 Recently launched multi-center, randomized, placebo controlled longitudinal studies evaluating cardiovascular benefit of incretin-based therapies in individuals with type 2 diabetes (Source: http://www.clinicaltrials.gov).
From: Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins
Trial | Active drug | Category | Phase | N | Start | Duration |
|---|---|---|---|---|---|---|
EXSCEL | Exenatide QW (weekly) | GLP-1 agonist | III | 9,500 | June 2010 | 6 3/4 years |
LEADER | Liraglutide | GLP-1 agonist | IV | 8,754 | August 2010 | 6 1/4 years |
TECOS | Sitagliptin | DPP-IV inhibitor | IV | 14,000 | December 2008 | 6 years |
SAVOR-TIMI53 | Saxagliptin | DPP-IV inhibitor | IV | 12,000 | May 2010 | 5 years |